Amiodarone and homogeneity of ventricular repolarization and refractoriness

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 1, Issue 4, 1996, Pages 265-270

  Singh, Bramah N ^a,b,c  

^a Department of Medicine   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 14544300591     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/107424849600100401     Document Type: Editorial

References (44)

1. Singh BN. Amiodarone: historical development and pharmacologic profile. Am Heart J 106:788, 1983.
2. Charlier R, Deltour G, Baudine A,et al.Pharmacology of amiodarone: an antianginal drug with a new biological profile. Arzneimittelforschung 18:1408, 1968.
3. Singh BN, Vaughan Williams EM. The effect of amiodarone: a new anti-anginal drug, on cardiac muscle. Br J Pharmacol 39:657, 1970.
4. Singh BN, Vaughan Williams EM. A third class of antiarrhythmic actions? Effects on atrial and ventricular intracellular potentials and other pharmacological actions on cardiac muscle, of MJ 1999 and AH 3474. Br J Pharmacol 39:675, 1970.
5. The CASCADE Investigators. The Cascade Study: randomized antiarrhythmic drug therapy in survivors of cardiac arrest in Seattle. Am J Cardiol 72:280, 1983.
6. Singh BN. Implantable cardioverter defibrillators: not the ultimate gold standard for gauging therapy for ventricular tachycardia and fibrillation? Am J Cardiol 73:1211, 1991.
7. Zipes DP. Implantable cardioverter-defibrillator: life-saver or device looking for a disease? Circulation 91:2115, 1994.
8. Nademanee K, Singh BN, Hendrickson J,et al.Amiodarone in refractory life-threatening ventricular arrhythmias. Ann Intern Med 98:57, 1983.
9. Weinberg BA, Miles WM, Klein LS, Bolander JE,et al.Five-year follow-up of 589 patients treated with amiodarone. Am Heart J 125:109, 1993.
10. Singh SN, Gross-Fisher S, Fletcher RD, Singh BN, el al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmias. N Engl J Med 33:77, 1995.
11. Middlekauff HR, Wiener I, Saxon LA, Stevenson WG. Low-dose amiodarone for atrial fibrillation: time for a prospective study? Ann Intern Med 116:1017, 1992.
12. Chun S, Sager PT, Stevenson WG, Nademanee K, Middlekauff HR, Singh B. Amiodarone is highly effective in maintaining NSR in refractory atrial fibrillation/flutter. Am J Cardiol 76:47, 1995.
13. Doval HC, Nul DR, Vancelli HO, Elizari M, Randomized trial of low-dose amiodarone in severe congestive heart failure. Lancet 344:493, 1994.
14. Nademanee K, Singh BN, Stevenson WG, Weiss JN. Amiodarone in post-Mi patients. Circulation 88:764, 1993.
15. Singh BN, Ahmed R. Class III antiarrhythmic drugs. Curr Opin Cardiol 19:12, 1994.
16. Holnloser S, Klingenheben T, Singh BN. Amiodarone-associated proarrhythmic effects: a review with special reference to torsade de pointes tachycardia. Ann Intern Med 121:529, 1994.
17. Nasir N, Swama US, Boahene KA, Doyle TK, Pacifico A. Therapy of sustained ventricular arrhythmias with amiodarone: prediction of efficacy with serial electrophysiologic studies. J Cardiovasc Pharmacol Therapeut 1:123, 1996.
18. Venkatesh N, Somani P, Bersohn M, Phair HR, Kato R, Singh BN. Electropharamcology of amiodarone: absence of relationship to serum, myocardial and cardiac sarcolemmal membrane drug concentrations. Am Heart J 112:916, 1986.
19. Antimisiaris M, Sarma JSM, Schoenbaum MP, Sharma PP, Venkataraman K, Singh BN. Effects of amiodarone on the circadian rhythm and power spectral changes of heart rate and QT interval: significance for the control of sudden cardiac death. Am Heart J 128:884, 1994.
20. Charlier R. Cardiac actions in the dog of a new antagonist of adrenergic excitation which does not produce competitive blockade of adrenoceptors. Br J Pharmacol 39:668, 1970.
21. Singh BN, Venkatesh N, Nademanee K, Josephson MA, Kannan R. The historical development, cellular electrophysiology and clinical pharmacology of amiodarone. Prog Cardiovasc Dis 31:249, 1989.
22. Mason JW, Hondeghem LM, Katzung BG. Block of inactivated sodium channels and of depolarization induced automaticity in guinea-pig papillary muscle by amiodarone. Circ Res 55:277, 1984.
23. Singh BN. The coming of age of class III antiarrhythmic principle: retrospective and future trends. Am J Cardiol (in press).
24. Singh BN. Advantages of beta-blockers versus antiarrhythmic drugs and calcium-channel antagonists in secondary prevention in survivors of myocardial infarction. Am J Cardiol 66:9, 1990.
25. Jervell A, Lange-Nielsen F. Congenital deaf-mutism, functional heart disease with the prolongation of the QT interval and sudden death. Am Heart J 54:59, 1957.
26. Singh BN, Hauswirth O. Comparative mechanisms of action of antiarrhythmic drugs. Am Heart J 87:367, 1974.
27. Sager PT, Uppal P, Follmer CT, Antimisiaris M, Pruitt C, Singh BN. The frequency-dependent electrophysiologic effects of amiodarone in humans. Circulation 88:1063, 1993.
28. Papp J Gy, Nemeth M, Krassoki I,et al.Differential electrophysiologic effects of amiodarone in canine Purkinje fibers and ventricular muscle. J Cardiovasc Pharmacol Therapeut 1:287, 1996.
29. Yabek S, Kato R, Singh BN. Acute electrophysiologic effects of amiodarone and desethylamiodarone in isolated cardiac muscle. J Cardiovasc Pharmacol 8:197, 1985.
30. Aomine M. Multiple electrophysiological actions of amiodarone in guinea pig heart. Naunyn Schmiedeberg Arch Pharmacol 338:589, 1988.
31. Scheinman MM. Levine JH. Cannom DS, Kopelman FT, Chilson DA, Platia EV, Wilber DJ, Kowey PR, for the Intravenous Amiodarone Multicenter Investigators Group. Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. Circulation 92:3264, 1995.
32. Kowey PR, Levine JH, Pacifica A, et al., for the Intravenous Amiodarone Multicenter Investigators Group. Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent hemodynamically destabilizing ventricular tachycardia and fibrillation. Circulation 92:3255, 1995.
33. Gallagher JD. Bianchi J, Gessman LJ. A comparison of the electrophysiologic effects of acute and chronic amiodarone administration of canine Purkinje fibers. J Cardiovasc Pharmacol 13:723, 1989.
34. Han J, Moe GK. Non-uniform recovery of excitability in ventricular muscle. Circ Res 14:44, 1964.
35. Antzelevitch C, Sicouri S, Litovsky S, Lukas A,et al.Heterogeneity within the ventricular wvall. Circ Res 69:1427, 1991.
36. Takanaka C, Singh BN. Barium-induced non-driven action potentials as a model of triggered potentials from early afterdepolarization: significance of slow-channel activity and differing effects of quinidine and amiodarone. J Am Coll Cardiol 15:213, 1990.
37. Nishimura M, Follmer CH, Singer DH. Amiodarone blocks calcium current in single guinea-pig ventricular myocytes. J Pharmacol Exp Ther 251:650, 1989.
38. Varro A, Virag L, Papp J Gy. Comparison of the chronic and acute effects of amiodarone on the calcium and potassium currents in isolated rabbit cardiac myocytes. Br J Pharmacol 117:1181, 1996.
39. Perkiomaki JS, Koistinen MJ, Yli-Mayry S, Huikuri HV. Dispersion of QT interval in patients with and without susceptibility to ventricular tachyarrhythmias after previous myocardial infarction. J Am Coll Cardiol 26:174, 1995.
40. Hii JTY, Wyse DG, Gillis AM, Dugg HJ, Solylo MS, Mitchell BLB. Precordial QT interval dispersion as a marker of torsades de pointes: disparate effects of class Ia antiarrhythmic drugs and amiodarone. Circulation 86:1372, 1992.
41. Cui G, Sen L, Uppal P, Sager PT, Singh BN. Effects of amiodarone, sematilide and sotalol on QT dispersion. Am J Cardiol 74:896, 1994.
42. Antzelevitch C, Sicouri S. Clinical relevance of cardiac arrhythmias generated by afterdepolarizations. J Am Coll Cardiol 23:259, 1994.
43. Sicouri S, Moro S, Siri LN, Elizari M,et al.Chronic amiodarone delays ventricular repolarization and reduces transmural dispersion of repolarization in the caninc heart. Pace 1:638, 1996.
44. Waldo AL, Camm JA, deRuyter H. et al., for the SWORD Investigators. Effect of d-sotalol on mortality in patients with ventricular dysfunction after recent and remote myocardial infarction. Lancet 348:7, 1996.